1. Filed/ regulartory approval
LEO Pharma pipeline overview
2017 Q4
Project
Description
Discovery
Ph1
Ph2a
Ph2b
Ph3
Filed/ regulartory approval
Launch
PoC
Psoriasis
Topical formulation
LP0053
The first fixed dose combination foam approved for the treatment of psoriasis vulgaris. Launched in several markets including the US and Europe.
Topical formulation
LP0076
A topical treatment approved for people with body and scalp psoriasis providing a simple portable solution. Launched in several markets including the US and Europe. Development ongoing to bring the treatment to Japan.
Brodalumab
LP0160
An IL-17 receptor monoclonal antibody under regulatory
review for people with psoriasis.
Oral PDE4i
LP0058
A systemic anti-inflammatory compound intended to offer an oral
long-term treatment option for people with moderate to severe psoriasis.
Eczema
Tralokinumab
LP0162
An IL-13 anti-inflammatory monoclonal antibody under
development for people with atopic dermatitis
JAK Topical
LP0133
A topical treatment for inflammatory skin diseases using a pan-JAK inhibitor, intended to offer an improved safety profile compared to topical steroids.
SEGRA
LP0155
A selective glucocorticoid non-steroidal receptor agonist for topical treatment of atopic dermatitis, intended to offer an improved safety profile compared to topical steroids.
ARGX-112
LP0145
An anti-inflammatory monoclonal antibody
for the treatment of atopic dermatitis.
To be used externally
Actinic Keratosis
Ingenol disoxate
LP0084
A novel topical compound for the treatment
of actinic keratosis in large areas.